Frataxin Expression Modulation Through GAA Repeat-Binding Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no cure for Friedreich's ataxia (FRDA), a rare autosomal recessive neurodegenerative disease caused by abnormal GAA trinucleotide repeat expansions in the frataxin (FXN) gene, leading to reduced frataxin protein expression and progressive neurological and cardiac complications.
Innovation Solution
Development of agents with a formula A-L-B, where A is a triazolodiazepine Brd4 binding moiety, B is a polyamide nucleic acid binding moiety, and L is a linker, specifically designed to increase mRNA and protein levels of frataxin by binding to GAA oligonucleotide repeats, thereby modulating transcription.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GAA trinucleotide repeat expansions are present in the frataxin gene, then transcriptional repression occurs and frataxin protein expression is reduced, but no current therapy can restore frataxin levels
Solution Approach 1:
The patent uses polyamide compounds as intermediary molecules that bind to the GAA repeat sequences in the frataxin gene promoter region. These polyamides act as mediators between the abnormal DNA sequence and the transcription machinery, blocking the repressive effect of the repeat expansion and restoring normal transcription and protein expression levels.
Solution Approach 2:
The invention changes the chemical and structural parameters of the binding molecules by designing specific polyamide compounds with defined molecular weights, binding affinities, and selectivities. By optimizing these parameters, the polyamides effectively compete with the GAA repeat sequences for transcription factor binding, thereby restoring frataxin expression.
2Quantity of substance
If polyamide compounds are designed to specifically bind GAA oligonucleotide repeats, then frataxin mRNA expression levels increase, but the molecular complexity of the therapeutic agent increases
Solution Approach 1:
The polyamide compounds are segmented into specific functional modules: a binding moiety that recognizes and binds to the GAA repeat sequence, a linker region that provides spatial flexibility, and a functional group that interacts with transcription factors. This segmentation allows each component to be optimized independently while maintaining overall simplicity.
Solution Approach 2:
The polyamide compounds exhibit local quality by concentrating their binding activity at specific sites within the promoter region where GAA repeats are located. The molecules are designed to bind specifically to these repeat sequences rather than uniformly across the entire gene, thereby achieving localized restoration of transcription without requiring complex genome-wide intervention.
3Quantity of substance
If existing therapies are developed to treat FRDA, then frataxin levels can be restored, but the cost and complexity of developing new therapies increases
Solution Approach 1:
The polyamide compounds are designed to be self-targeting, automatically binding to the GAA repeat sequences in the frataxin gene without requiring external delivery systems or complex formulation. The molecules self-localize to the promoter region and exert their effect directly, simplifying the manufacturing and administration processes compared to gene therapy or protein replacement approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agents significantly increase frataxin mRNA and protein levels in FRDA patient cells, potentially ameliorating symptoms and slowing disease progression.
Implementation Method 1
B is a polyamide that is a nucleic acid binding moiety that specifically binds to one or more repeats of a GAA oligonucleotide sequence
Implementation Method 2
A is a triazolodiazepine Brd4 binding moiety
Data Source
Figure 1A~1B
Figure 1C
Figure 2
AI summary
The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.